EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE
Pre-Launchefavirenz; lamivudine; tenofovir disoproxil fumarate
NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
Priority Review
EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE (efavirenz; lamivudine; tenofovir disoproxil fumarate) by Hetero is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ].
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
A fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate—three antiretroviral agents with proven activity against HIV-1. This oral combination is designed to simplify HIV treatment regimens by delivering three drugs in a single tablet formulation. The product targets treatment-naïve and treatment-experienced patients with HIV-1 infection.
PRE_LAUNCH
As a pre-launch product from Hetero, this represents an opportunity to build commercial infrastructure and launch team capabilities in a competitive HIV treatment space.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch product offers exposure to HIV market dynamics, global health initiatives, and Hetero's generic/biosimilar business model. Career growth depends on successful regulatory approval and the company's ability to scale commercial operations in emerging markets where fixed-dose combinations are high-demand.
Generic/Brand Product ManagerMedical Science Liaison
Worked on EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.